Ultradent Products Inc
$13.4M 17,574 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Blueprint Medicines Corporation
Blueprint Medicines Corporation reported $13,456,295.75 across General Payments, Research, and Ownership to 8,586 physicians and teaching hospitals across 9,648 transactions.
- $13.5M Top 10% payer
- All-tracks total
- 9,648 Top quartile volume
- Transactions
- 8,586 Top quartile reach
- Recipients
- −$40.7K
- General Payments vs PY2023
Blueprint Medicines Corporation reported $13,456,295.75 across all CMS Open Payments tracks (General + Research + Ownership) to 8,586 physicians and teaching hospitals in Program Year 2024 - ranking #137 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $1,925,373.91, averaging $1.6K per recipient.
How Blueprint Medicines Corporation's $13.5M all-tracks total breaks down
Blueprint Medicines Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
89/100
Total payments
A
100/100
Transaction volume
B
80/100
Physician reach
C
75/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer blueprint-medicines-corporation Blueprint Medicines Corporation
$13.5M · #137/1,925 · 0.1% industry · PY2024
- TOT $13.5M
- RANK #137
- SHARE 0.1%
- TXN 9,648
- RCP 8,586
- CAT 8
- GEN $1.9M
- ΔGEN −$40.7K
- TOP1 6.9%
- PY 2024
Volume peers
Nearest volume peer: Ultradent Products Inc ($13.4M)
Blueprint Medicines Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Blueprint Medicines Corporation's CMS-reported General Payments decreased by $40.7K (−2.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BLUEPRINT MEDICINES CORPORATIONPY2023: BLUEPRINT MEDICINES CORPORATIONPY2024: Blueprint Medicines Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,966,096.54
- PY2024
- $1,925,373.91
What the Data Shows for Blueprint Medicines Corporation
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Blueprint Medicines Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Honoraria" leads the 8-category general-payment breakdown below at $1.0M (54.4% of General Payments, 458 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Honoraria" leads Blueprint Medicines Corporation's 8-category general-payment breakdown at $1.0M, 54.4% of the reported total.
Blueprint Medicines Corporation reports 8 general-payment categories - the top three are Honoraria (54.4%), Food and Beverage (13.7%), and Consulting Fee (12.8%). The remaining 5 categories make up 19.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Blueprint Medicines Corporation files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Blueprint Medicines Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $1.0M | 458 | 54.4% |
| Food and Beverage | $263.2K | 7,455 | 13.7% |
| Consulting Fee | $246.2K | 102 | 12.8% |
| Travel and Lodging | $173.0K | 543 | 9.0% |
| Compensation for Services Other Than Consulting | $164.7K | 17 | 8.6% |
| Grant | $27.5K | 2 | 1.4% |
| Education | $2.2K | 7 | 0.1% |
| Charitable Contribution | $320.00 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $499,973.34 (26.0%) of $1,925,373.91 in this company's General Payments records across 4,470 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Blueprint Medicines Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Sandra Richman
$133,500.00 across 12 reported transactions
- 2
Amro Elshoury
$107,085.68 across 98 reported transactions
- 3
James Mccloskey
$92,950.75 across 104 reported transactions
- 4
Salman Fazal
$86,549.35 across 86 reported transactions
- 5
Ann Maitland
$79,887.56 across 91 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Blueprint Medicines Corporation ranks #137 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,534 of 1,838 by HHI (bottom 17% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Otto Bock HealthCare LP : $1.0K total payments, HHI 232
- Sioux Surgical Inc : $53.3K total payments, HHI 232
- Kedplasma LLC : $3.2M total payments, HHI 230
- Kulzer, LLC : $187.8K total payments, HHI 230
- Paladin Technology Solutions : $20.4K total payments, HHI 226
- Pharming Healthcare, Inc. : $1.6M total payments, HHI 225
- Blueprint Medicines Corporation (this company) : $1.9M total payments, HHI 221
- Azurity Pharmaceuticals, Inc. : $281.2K total payments, HHI 218
- Mirum Pharmaceuticals, Inc. : $1.2M total payments, HHI 218
- Biofrontera Inc. : $252.6K total payments, HHI 217
- Steelhead Surgical Inc : $51.2K total payments, HHI 217
- Artivion, Inc. : $449.9K total payments, HHI 216
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Blueprint Medicines Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Blueprint Medicines Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Blueprint Medicines Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
BeiGene USA, Inc.
$13.4M 11,760 recipients
Compare payment profiles
Alcon Vision LLC
$13.4M 94,278 recipients
Compare payment profiles
Centinel Spine, LLC
$13.6M 858 recipients
Compare payment profiles
Lazurite Inc.
$13.6M 7 recipients
Compare payment profiles
Atricure, Inc.
$13.7M 28,870 recipients
Compare payment profiles
Put this to use
Blueprint Medicines Corporation ranks #137 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Blueprint Medicines Corporation sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Blueprint Medicines Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.